During the recent session, Fortress Biotech Inc (NASDAQ:FBIO)’s traded shares were 0.42 million, with the beta value of the company hitting 1.67. At the last check today, the stock’s price was $2.28, reflecting an intraday gain of 12.82% or $0.25. The 52-week high for the FBIO share is $3.07, that puts it down -34.65 from that peak though still a striking 40.35% gain since the share price plummeted to a 52-week low of $1.36. The company’s market capitalization is $63.07M, and the average intraday trading volume over the past 10 days was 0.75 million shares, and the average trade volume was 647.03K shares over the past three months.
Fortress Biotech Inc (FBIO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. FBIO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.75.
Fortress Biotech Inc (NASDAQ:FBIO) trade information
Fortress Biotech Inc (FBIO) registered a 12.82% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 12.82% in intraday trading to $2.28, hitting a weekly high. The stock’s 5-day price performance is 26.23%, and it has moved by -0.67% in 30 days. Based on these gigs, the overall price performance for the year is -15.07%. The short interest in Fortress Biotech Inc (NASDAQ:FBIO) is 2.62 million shares and it means that shorts have 4.57 day(s) to cover.
Fortress Biotech Inc (FBIO) estimates and forecasts
Statistics show that Fortress Biotech Inc has outperformed its competitors in share price, compared to the industry in which it operates. Fortress Biotech Inc (FBIO) shares have gone up 29.81% during the last six months, with a year-to-date growth rate more than the industry average at 61.28% against 16.70. In the rating firms’ projections, revenue will decrease -31.22% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 15.58M as predicted by 2 analyst(s).
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 22.28%. While earnings are projected to return 58.60% in 2025, the next five years will return 25.50% per annum.
FBIO Dividends
Fortress Biotech Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Fortress Biotech Inc (NASDAQ:FBIO)’s Major holders
Fortress Biotech Inc insiders own 21.21% of total outstanding shares while institutional holders control 15.78%, with the float percentage being 20.03%.
